INS and coronary artery disorder: Current clinical guidelines discourage measuring insulin concentration in the assessment of cardiometabolic risk, because knowledge of this value does not alter patient management in a prevention scheme that focuses in treatment of high-risk patients [19], in spite of the strong known independent association of insulin with ischemic heart disease [21].